E. Goekkurt

A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Background Patients with MSI-H/dMMR mCRC treated with chemotherapy have poorer outcomes than patients with microsatellite stable/MMR proficient mCRC. Pembrolizumab monot...

T. Andre ;

Sara Lonardi ;

S. Abdullaev ;

M. Lei ;

L. Jensen ;

C. De la Fouchardiere ;

E. Elez ;

J. Bennouna ;

G. Mendez ;

J. Li ;

Eric Van Cutsem , MD, PhD;

E. Goekkurt ;

T. Chen ;

Takayuki Yoshino , MD, PhD;

06/27/2022

Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy – final results of the phase II RE-ExPEL study

BackgroundBased on results of prior trials (TAGS, REGARD, RAINBOW), it seems promising to combine Ramucirumab (Ram) beyond progression (PD) with TAS-102 (trifluridine/tipiracil). The purp...

Alexander Stein ;

Timorshah Habibzada ;

Peter Herhaus ;

E. Goekkurt ;

Disorn Sookthai ;

Tanita Brulin ;

Kristina Ihrig ;

Claudia Pauligk ;

Salah-Eddin Al-Batran , MD;

Sylvie Lorenzen ;

Thorsten Goetze ;

06/25/2023